Mandate

Vinge advises Zellis Group, a portfolio company of Apax Partners, in connection with the acquisition of Benify

Vinge has, together with Kirkland & Ellis, advised Zellis Group, a portfolio company of funds advised by Apax Partners LLP (“Apax”), in connection with the acquisition of Benify, a provider of employee benefits administration software, from Vitruvian Partners and the other shareholders.

As part of the transaction, Benify will be combined with Zellis Group’s benefits administration and employee engagement software business, Benefex, and Vitruvian Partners will become a minority investor in the Zellis Group alongside the Apax Funds. Together, Benefex and Benify will create a leading global benefits, reward, recognition, and employee engagement software provider with an enhanced value proposition to customers globally. Completion of the transaction is subject to customary closing conditions.

Vinge’s team consisted of among others Jonas Bergström, Anna Jonsson, Nicolas Ek, Johan Severinsson and Gustav Bergengren (M&A), Nils Unckel and Anton Sjökvist (Financial Regulatory), Albert Wållgren and Arvid Weimers (Banking and Finance), Oskar Larsson (Commercial Contracts) and Emelie Svensäter Jerntorp and Carolina Lundh (Employment).

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025